Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome.

Published

Journal Article

Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening condition characterized by small-vessel thrombi and a rapid onset of multiorgan system failure associated with systemic inflammatory response syndrome. Current treatment options include anticoagulants, corticosteroids, plasma exchange, and intravenous immunoglobulin, but these are not always effective. Rituximab, a chimeric anti-CD20 monoclonal antibody, may help eliminate autoreactive B cells and thus limit the rapid inflammatory process involved in CAPS. We describe the use of rituximab in the successful initial management of a probable case of pediatric CAPS.

Full Text

Duke Authors

Cited Authors

  • Nageswara Rao, AA; Arteaga, GM; Reed, AM; Gloor, JM; Rodriguez, V

Published Date

  • April 2009

Published In

Volume / Issue

  • 52 / 4

Start / End Page

  • 536 - 538

PubMed ID

  • 19061212

Pubmed Central ID

  • 19061212

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

Digital Object Identifier (DOI)

  • 10.1002/pbc.21878

Language

  • eng

Conference Location

  • United States